Glucagon-like peptide-2 (GLP-2) response to enteral intake in children during anti-cancer treatment

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

Glucagon-like peptide-2 (GLP-2) response to enteral intake in children during anti-cancer treatment. / Andreassen, B U; Paerregaard, A; Schmiegelow, K; Rechnitzer, C; Heilman, C; Hartmann, B; Holst, Jens Juul; Michaelsen, K F.

In: Journal of Pediatric Gastroenterology and Nutrition, Vol. 40, No. 1, 01.2005, p. 48-53.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Andreassen, BU, Paerregaard, A, Schmiegelow, K, Rechnitzer, C, Heilman, C, Hartmann, B, Holst, JJ & Michaelsen, KF 2005, 'Glucagon-like peptide-2 (GLP-2) response to enteral intake in children during anti-cancer treatment', Journal of Pediatric Gastroenterology and Nutrition, vol. 40, no. 1, pp. 48-53.

APA

Andreassen, B. U., Paerregaard, A., Schmiegelow, K., Rechnitzer, C., Heilman, C., Hartmann, B., Holst, J. J., & Michaelsen, K. F. (2005). Glucagon-like peptide-2 (GLP-2) response to enteral intake in children during anti-cancer treatment. Journal of Pediatric Gastroenterology and Nutrition, 40(1), 48-53.

Vancouver

Andreassen BU, Paerregaard A, Schmiegelow K, Rechnitzer C, Heilman C, Hartmann B et al. Glucagon-like peptide-2 (GLP-2) response to enteral intake in children during anti-cancer treatment. Journal of Pediatric Gastroenterology and Nutrition. 2005 Jan;40(1):48-53.

Author

Andreassen, B U ; Paerregaard, A ; Schmiegelow, K ; Rechnitzer, C ; Heilman, C ; Hartmann, B ; Holst, Jens Juul ; Michaelsen, K F. / Glucagon-like peptide-2 (GLP-2) response to enteral intake in children during anti-cancer treatment. In: Journal of Pediatric Gastroenterology and Nutrition. 2005 ; Vol. 40, No. 1. pp. 48-53.

Bibtex

@article{27b0c13760f441c99eda668ed45e4046,
title = "Glucagon-like peptide-2 (GLP-2) response to enteral intake in children during anti-cancer treatment",
abstract = "BACKGROUND: Intestinal dysfunction is frequent in cancer and during anti-cancer treatment. Glucagon-like peptide-2 (GLP-2) is secreted in a nutrition-dependent manner from the intestinal enteroendocrine L-cells. It accelerates crypt cell proliferation and nutrient absorption, inhibits enterocyte apoptosis and decreases mucosal permeability. Lack of GLP-2 may increase the risk of malabsorption and intestinal bacterial translocation. The aim of this study is to evaluate meal stimulated secretion of GLP-2 in children with cancer undergoing anti-cancer treatment.METHODS: Plasma-GLP-2 analysis after an overnight fast and 1 hour after intake of a mixed test meal. Data on gastrointestinal toxicity, blood neutrophile counts and food records were included in the analysis.RESULTS: Forty-four meal stimulation tests were performed in 25 children (median age, 6.0 years; range, 2.5-19) during anti-cancer treatment. Median GI toxicity score was 5 (range, 0-15), and mean energy intake was 62.4% of recommended values. P-GLP-2 values increased from mean (SD) 38 (18) to 63 (51) pmol/l (P < 0.0001). Twelve of the meal stimulation tests (28%) resulted in a p-GLP-2 increase >2 fold, which is assumed to be the lower limit of normal values. The increase was strongly dependent on the energy intake (r = 0.62, P < 0.0001), while toxicity score and neutrophile count had no significant influence (multiple regression).CONCLUSION: In children treated with anti-cancer therapy, GLP-2 secretion seems to be normal if the enteral energy intake is sufficient. Insufficient GLP-2 secretion could influence the gastrointestinal problems seen in the children with a low enteral energy intake.",
keywords = "Adolescent, Antineoplastic Combined Chemotherapy Protocols, Child, Child, Preschool, Diet Records, Energy Intake, Enteral Nutrition, Female, Glucagon-Like Peptide 2, Glucagon-Like Peptides, Humans, Male, Neoplasms, Neutrophils, Nutritional Requirements, Nutritional Status, Peptides",
author = "Andreassen, {B U} and A Paerregaard and K Schmiegelow and C Rechnitzer and C Heilman and B Hartmann and Holst, {Jens Juul} and Michaelsen, {K F}",
year = "2005",
month = jan,
language = "English",
volume = "40",
pages = "48--53",
journal = "Journal of Pediatric Gastroenterology and Nutrition",
issn = "0277-2116",
publisher = "Lippincott Williams & Wilkins",
number = "1",

}

RIS

TY - JOUR

T1 - Glucagon-like peptide-2 (GLP-2) response to enteral intake in children during anti-cancer treatment

AU - Andreassen, B U

AU - Paerregaard, A

AU - Schmiegelow, K

AU - Rechnitzer, C

AU - Heilman, C

AU - Hartmann, B

AU - Holst, Jens Juul

AU - Michaelsen, K F

PY - 2005/1

Y1 - 2005/1

N2 - BACKGROUND: Intestinal dysfunction is frequent in cancer and during anti-cancer treatment. Glucagon-like peptide-2 (GLP-2) is secreted in a nutrition-dependent manner from the intestinal enteroendocrine L-cells. It accelerates crypt cell proliferation and nutrient absorption, inhibits enterocyte apoptosis and decreases mucosal permeability. Lack of GLP-2 may increase the risk of malabsorption and intestinal bacterial translocation. The aim of this study is to evaluate meal stimulated secretion of GLP-2 in children with cancer undergoing anti-cancer treatment.METHODS: Plasma-GLP-2 analysis after an overnight fast and 1 hour after intake of a mixed test meal. Data on gastrointestinal toxicity, blood neutrophile counts and food records were included in the analysis.RESULTS: Forty-four meal stimulation tests were performed in 25 children (median age, 6.0 years; range, 2.5-19) during anti-cancer treatment. Median GI toxicity score was 5 (range, 0-15), and mean energy intake was 62.4% of recommended values. P-GLP-2 values increased from mean (SD) 38 (18) to 63 (51) pmol/l (P < 0.0001). Twelve of the meal stimulation tests (28%) resulted in a p-GLP-2 increase >2 fold, which is assumed to be the lower limit of normal values. The increase was strongly dependent on the energy intake (r = 0.62, P < 0.0001), while toxicity score and neutrophile count had no significant influence (multiple regression).CONCLUSION: In children treated with anti-cancer therapy, GLP-2 secretion seems to be normal if the enteral energy intake is sufficient. Insufficient GLP-2 secretion could influence the gastrointestinal problems seen in the children with a low enteral energy intake.

AB - BACKGROUND: Intestinal dysfunction is frequent in cancer and during anti-cancer treatment. Glucagon-like peptide-2 (GLP-2) is secreted in a nutrition-dependent manner from the intestinal enteroendocrine L-cells. It accelerates crypt cell proliferation and nutrient absorption, inhibits enterocyte apoptosis and decreases mucosal permeability. Lack of GLP-2 may increase the risk of malabsorption and intestinal bacterial translocation. The aim of this study is to evaluate meal stimulated secretion of GLP-2 in children with cancer undergoing anti-cancer treatment.METHODS: Plasma-GLP-2 analysis after an overnight fast and 1 hour after intake of a mixed test meal. Data on gastrointestinal toxicity, blood neutrophile counts and food records were included in the analysis.RESULTS: Forty-four meal stimulation tests were performed in 25 children (median age, 6.0 years; range, 2.5-19) during anti-cancer treatment. Median GI toxicity score was 5 (range, 0-15), and mean energy intake was 62.4% of recommended values. P-GLP-2 values increased from mean (SD) 38 (18) to 63 (51) pmol/l (P < 0.0001). Twelve of the meal stimulation tests (28%) resulted in a p-GLP-2 increase >2 fold, which is assumed to be the lower limit of normal values. The increase was strongly dependent on the energy intake (r = 0.62, P < 0.0001), while toxicity score and neutrophile count had no significant influence (multiple regression).CONCLUSION: In children treated with anti-cancer therapy, GLP-2 secretion seems to be normal if the enteral energy intake is sufficient. Insufficient GLP-2 secretion could influence the gastrointestinal problems seen in the children with a low enteral energy intake.

KW - Adolescent

KW - Antineoplastic Combined Chemotherapy Protocols

KW - Child

KW - Child, Preschool

KW - Diet Records

KW - Energy Intake

KW - Enteral Nutrition

KW - Female

KW - Glucagon-Like Peptide 2

KW - Glucagon-Like Peptides

KW - Humans

KW - Male

KW - Neoplasms

KW - Neutrophils

KW - Nutritional Requirements

KW - Nutritional Status

KW - Peptides

M3 - Journal article

C2 - 15625426

VL - 40

SP - 48

EP - 53

JO - Journal of Pediatric Gastroenterology and Nutrition

JF - Journal of Pediatric Gastroenterology and Nutrition

SN - 0277-2116

IS - 1

ER -

ID: 132054005